A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Record History

See every version on ClinicalTrials.gov ↗

1. Minor Oct 9, 2026 Trial sites expanded: 23 → 26 locations

   • Eligibility criteria expanded, about 68 words
2. Notable Sep 8, 2026 Start date: Aug 30, 2026 to Oct 30, 2026

   • Trial sites expanded: 20 → 23 locations

   v10
3. Notable Aug 24, 2026 Primary endpoint(s) modifiedv9 Show 7 more changesShow less

   • Enrollment increased: 88 → 176 participants
   • Primary completion pushed from Nov 30, 2026 to Mar 30, 2027
   • Study completion pushed from Mar 30, 2027 to Jul 31, 2027
   • Eligibility criteria expanded, about 140 words
   • Secondary endpoints revised (3)
   • Site details revised at 1 of 20 sites
   • Study title expanded, about 1 word
4. Notable Aug 3, 2026 Start date: Jun 30, 2026 to Aug 30, 2026

   • Trial sites expanded: 15 → 20 locations

   v8
5. Minor Jul 13, 2026 Trial sites expanded: 11 → 15 locationsv7
6. Notable Jun 2, 2026 Start date: May 29, 2026 to Jun 30, 2026

   • Study sites: 10 to 11

   v6
7. Notable May 15, 2026 Recruitment opened

   • Start date: Apr 29, 2026 to May 29, 2026
   • Trial sites expanded: 3 → 10 locations

   v5
8. Notable Mar 9, 2026 Start date: Feb 27, 2026 to Apr 29, 2026

   • Study sites: 1 to 3

   v4
9. Minor Feb 12, 2026 Study sites: 0 to 1

   • Start date: Jan 29, 2026 to Feb 27, 2026

   v3
10. Notable Jan 20, 2026 Start date: Dec 29, 2025 to Jan 29, 2026v2
11. Minor Dec 16, 2025 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.